Novel Therapies in Asthma

Abstract

Asthma is one of the most common conditions seen in clinical practice and carries both a significant disease burden in terms of patient morbidity and a high economic burden in both direct and indirect costs. Despite this, it remains a comparatively poorly understood disease, with only modest advances in treatment over the past decade. Corticosteroids remain the cornerstone of therapy. Both patient compliance with medications and physician adherence to evidence-based guidelines are often poor, and a high percentage of patients continue to have inadequately controlled disease even with optimal therapy. Following a contextual overview of the current treatment guidelines, this review focuses on novel asthma therapies, beginning with the introduction of the leukotriene receptor antagonist zafirlukast in the 1990s, continuing through advanced endoscopic therapy and into cytokine-directed biologic agents currently in development. Along with clinically relevant biochemistry and pharmacology, the evidence supporting the place of these therapies in current guidelines will be highlighted along with data comparing these agents with more conventional treatment. A brief discussion of other drugs, such as those developed for unrelated conditions and subsequently examined as potential asthma therapies, is included.

Lipoxygenase Pathway Mediates Increases of Airway Resistance and Lung Inflation Induced by Exposure to Nanotitanium Dioxide in Rats

“…Their known activities include contraction of bronchial smooth muscles, stimulation of vascular permeability, and attraction and activation of leukocytes [28]. Leukotrienes are known to be involved in obstructive pulmonary insufficiency [29, 30]. In fact, leukotriene antagonists are established therapeutic agents for asthma.…”

Human adipose tissue mesenchymal stromal cells and their extracellular vesicles act differentially on lung mechanics and inflammation in experimental allergic asthma

“…These drugs minimize inflammation and slow accompanying airway remodeling. However, as they are unable to revert established remodeling [2, 3], many patients still experience severe exacerbations or unsuccessful control of their symptoms [4, 5]. …”

Predicting phenotypes of asthma and eczema with machine learning

“…Asthma is the most common chronic disease in developed countries, however, the drug armamentarium available to manage the condition is modest[1]. There is increasing recognition that asthma is a heterogeneous disease with multiple endotypes, which may have similar clinical manifestations, or phenotypes, but different underlying pathophysiological causes[2,3].…”